The FDA has officially declared the semaglutide shortage over — and that decision carries real consequences for patients who had been relying on compounded, off-brand versions of Ozempic. Compounding pharmacies can no longer legally manufacture or sell these products. If you depend on semaglutide to manage Type 2 diabetes or another condition, here's what you need to understand about this shift and what options remain available to you.
What Is Ozempic?
Ozempic is a brand-name injectable prescription medication. Its active ingredient, semaglutide, is used primarily to help adults with Type 2 diabetes manage their blood sugar levels. Research has also shown meaningful cardiovascular benefits for certain patients, which has contributed to its widespread use.
How Does Ozempic Work?
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. GLP-1 is a hormone your small intestine releases naturally after you eat — it signals fullness to your brain, slows the rate at which your stomach empties, and stimulates insulin production. Ozempic mimics this process artificially, which is why it has also gained significant attention as a weight-loss aid beyond its primary diabetes indication.
Why Do So Many Patients Struggle to Afford Ozempic?
Even without a shortage, Ozempic sits well out of reach for a large portion of patients who need it. Without insurance, the monthly cost can exceed $900 to $1,200. Insurance coverage is inconsistent — some plans will only cover it for patients with advanced diabetes, while others exclude it entirely, particularly when prescribed for weight management. For anyone without adequate coverage, the out-of-pocket burden can be impossible to sustain.
How Did Off-Brand Ozempic Enter the Picture?
When demand for Ozempic surged, supply couldn't keep up. The FDA responded by allowing compounding pharmacies — which are licensed to prepare customized medications — to produce semaglutide formulations as a stopgap measure. For a period, this gave patients an alternative route to access the drug while manufacturers worked to restore inventory.
As of March 2025, the FDA has determined that the shortage is resolved and that sufficient supply exists to meet current demand. With that declaration, the legal basis for compounded semaglutide evaporated. Pharmacies that continue to produce or sell these products are now operating outside the law.
Why Did the FDA Move to Stop Compounded Semaglutide?
1. Compounded Drugs Bypass the FDA Safety Review
Unlike brand-name medications, compounded products are never subjected to the FDA's formal approval process. That means no independent verification of purity, potency, or consistency. Two batches from the same pharmacy could differ in ways that matter clinically.
2. Fraudulent Products Entered the Market
The FDA identified compounded semaglutide products carrying false or misleading labels. In some cases, legitimate pharmacy names were used without authorization. Patients who believed they were purchasing a reputable product were sometimes receiving something far less trustworthy.
3. Adverse Events Were Reported
The agency received reports of hospitalizations and other serious adverse effects linked to compounded semaglutide. Many of these cases involved dosing errors — either patients self-administering incorrectly or preparations that weren't formulated accurately.
4. Some Products Used Unapproved Salt Forms
Certain compounded versions contained semaglutide sodium or semaglutide acetate rather than the form used in FDA-approved Ozempic. These are chemically distinct compounds. Their safety profiles and therapeutic effectiveness have not been established, which the FDA identified as a meaningful risk to patients.
What This Change Means Going Forward
The FDA's confidence in the supply chain isn't universally shared. Some clinicians worry that demand — especially for weight management — still outpaces what manufacturers can reliably deliver, particularly for patients whose need is most acute. And regardless of supply, prices are unlikely to drop. Manufacturers have little financial incentive to reduce the cost of a medication this popular. For patients without robust insurance coverage, that reality means ongoing difficulty accessing a treatment that could meaningfully improve their health.
For a broader look at how regulatory changes may affect drug pricing and access, see our related post on new FDA rules that could raise medication prices and slow access.
How a Patient Assistance Program Can Help
If you're uninsured, underinsured, or simply facing costs you can't manage, a patient assistance program may be your most practical path forward. These programs — typically sponsored by the pharmaceutical manufacturers themselves — are designed to provide free brand-name medication or deeply discounted prescriptions to patients who qualify based on income and insurance status.
Through a manufacturer assistance program, eligible patients can receive the actual brand-name drug at little or no cost. The programs exist because manufacturers would rather provide medication to patients who can't afford it than see those patients go without treatment entirely.
Here's what enrollment in a medication assistance program typically offers:
- Free or heavily discounted prescriptions for patients who meet eligibility requirements
- Help navigating the application process, which can be paperwork-intensive
- Ongoing enrollment management so your access doesn't lapse unexpectedly
- Support for uninsured and underinsured patients who have no other affordable option
Don't Go Without the Medication You Need
ClariMeds is a full-service prescription assistance program that does the heavy lifting for you. We research every available source of brand name drug financial assistance, determine which programs you qualify for, and manage your enrollment from start to finish. Whether you need prescription help uninsured or you're looking for help paying for prescriptions your plan won't cover, ClariMeds works to make sure cost doesn't stand between you and your treatment.
If you're struggling to afford Ozempic or any other brand-name medication, start your application here and a ClariMeds team member will follow up within 24 hours to walk you through your options.
Frequently Asked Questions
Can I still buy off-brand Ozempic?
No. The FDA declared the semaglutide shortage over in March 2025. Compounding pharmacies are no longer legally permitted to produce or sell off-brand versions of Ozempic.
Why is Ozempic so expensive?
Without insurance, Ozempic typically costs between $900 and $1,200 per month. Many insurance plans restrict coverage to patients with advanced diabetes and won't cover it for weight loss, leaving many patients facing the full cost out of pocket.
Are compounded medications FDA-approved?
No. Compounded medications — including the semaglutide formulations that were sold during the shortage — are never FDA-approved. They do not go through the standard review process that verifies safety and effectiveness.
What safety concerns were linked to compounded semaglutide?
The FDA documented reports of hospitalizations, dosing errors, fraudulent labeling, and the use of unapproved salt forms such as semaglutide sodium and semaglutide acetate, which differ chemically from the ingredient in brand-name Ozempic.
How can I afford Ozempic without adequate insurance coverage?
A prescription assistance program like ClariMeds can help you apply for the manufacturer's own assistance program, which may provide Ozempic at no cost if you qualify. Get in touch with us to find out whether you're eligible.